金属-有机框架纳米系统克服肿瘤耐药的前景。

IF 4.6 Q1 ONCOLOGY 癌症耐药(英文) Pub Date : 2022-01-01 DOI:10.20517/cdr.2022.76
Huafeng Wang, Shi Li, Yiting Yang, Lei Zhang, Yinghao Zhang, Tianxiang Wei
{"title":"金属-有机框架纳米系统克服肿瘤耐药的前景。","authors":"Huafeng Wang,&nbsp;Shi Li,&nbsp;Yiting Yang,&nbsp;Lei Zhang,&nbsp;Yinghao Zhang,&nbsp;Tianxiang Wei","doi":"10.20517/cdr.2022.76","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer is one of the most harmful diseases in the world, which causes huge numbers of deaths every year. Many drugs have been developed to treat tumors. However, drug resistance usually develops after a period of time, which greatly weakens the therapeutic effect. Tumor drug resistance is characterized by blocking the action of anticancer drugs, resisting apoptosis and DNA repair, and evading immune recognition. To tackle tumor drug resistance, many engineered drug delivery systems (DDS) have been developed. Metal-organic frameworks (MOFs) are one kind of emerging and promising nanocarriers for DDS with high surface area and abundant active sites that make the functionalization simpler and more efficient. These features enable MOFs to achieve advantages easily towards other materials. In this review, we highlight the main mechanisms of tumor drug resistance and the characteristics of MOFs. The applications and opportunities of MOF-based DDS to overcome tumor drug resistance are also discussed, shedding light on the future development of MOFs to address tumor drug resistance.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"5 4","pages":"954-970"},"PeriodicalIF":4.6000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771744/pdf/","citationCount":"1","resultStr":"{\"title\":\"Perspectives of metal-organic framework nanosystem to overcome tumor drug resistance.\",\"authors\":\"Huafeng Wang,&nbsp;Shi Li,&nbsp;Yiting Yang,&nbsp;Lei Zhang,&nbsp;Yinghao Zhang,&nbsp;Tianxiang Wei\",\"doi\":\"10.20517/cdr.2022.76\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cancer is one of the most harmful diseases in the world, which causes huge numbers of deaths every year. Many drugs have been developed to treat tumors. However, drug resistance usually develops after a period of time, which greatly weakens the therapeutic effect. Tumor drug resistance is characterized by blocking the action of anticancer drugs, resisting apoptosis and DNA repair, and evading immune recognition. To tackle tumor drug resistance, many engineered drug delivery systems (DDS) have been developed. Metal-organic frameworks (MOFs) are one kind of emerging and promising nanocarriers for DDS with high surface area and abundant active sites that make the functionalization simpler and more efficient. These features enable MOFs to achieve advantages easily towards other materials. In this review, we highlight the main mechanisms of tumor drug resistance and the characteristics of MOFs. The applications and opportunities of MOF-based DDS to overcome tumor drug resistance are also discussed, shedding light on the future development of MOFs to address tumor drug resistance.</p>\",\"PeriodicalId\":70759,\"journal\":{\"name\":\"癌症耐药(英文)\",\"volume\":\"5 4\",\"pages\":\"954-970\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771744/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"癌症耐药(英文)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20517/cdr.2022.76\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"癌症耐药(英文)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20517/cdr.2022.76","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

癌症是世界上最有害的疾病之一,每年造成大量死亡。已经开发出许多治疗肿瘤的药物。然而,耐药性通常在一段时间后产生,这大大削弱了治疗效果。肿瘤耐药的特点是阻断抗癌药物的作用,抵抗细胞凋亡和DNA修复,逃避免疫识别。为了解决肿瘤耐药问题,许多工程化给药系统(DDS)已经被开发出来。金属有机骨架(MOFs)是一种新兴的、有前途的DDS纳米载体,具有高表面积和丰富的活性位点,使功能化更简单、更高效。这些特性使mof能够轻松实现与其他材料相比的优势。本文就肿瘤耐药的主要机制及MOFs的特点作一综述。讨论了基于mof的DDS在克服肿瘤耐药方面的应用和机遇,并对mof在解决肿瘤耐药方面的未来发展进行了展望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Perspectives of metal-organic framework nanosystem to overcome tumor drug resistance.

Cancer is one of the most harmful diseases in the world, which causes huge numbers of deaths every year. Many drugs have been developed to treat tumors. However, drug resistance usually develops after a period of time, which greatly weakens the therapeutic effect. Tumor drug resistance is characterized by blocking the action of anticancer drugs, resisting apoptosis and DNA repair, and evading immune recognition. To tackle tumor drug resistance, many engineered drug delivery systems (DDS) have been developed. Metal-organic frameworks (MOFs) are one kind of emerging and promising nanocarriers for DDS with high surface area and abundant active sites that make the functionalization simpler and more efficient. These features enable MOFs to achieve advantages easily towards other materials. In this review, we highlight the main mechanisms of tumor drug resistance and the characteristics of MOFs. The applications and opportunities of MOF-based DDS to overcome tumor drug resistance are also discussed, shedding light on the future development of MOFs to address tumor drug resistance.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.60
自引率
0.00%
发文量
0
期刊最新文献
Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma. NFE2L2 and ferroptosis resistance in cancer therapy. The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models. Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies. Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1